Lab
Memphis Pathology Laboratory
Memphis Pathology Laboratory was paid $61.43M by Medicaid between Jan 2018 and Dec 2024, across 429 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 13% of everything it billed.
33Billing provider infoMEMPHIS PATHOLOGY LABORATORY
MEMPHIS, TN 38134
MEMPHIS, TN 38134
33aNPI1548370745assigned 08/30/2006
33bProvider typeClinical Medical Laboratory
28Total paid$61.43M
24GClaims7,389,083
24DCodes billed429
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Tennessee
Rank by total paid#3 of 70
Median peer was paid$141K
This provider vs. median436×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,224,484 | $9.03M | |
| 2019 | 1,253,253 | $8.65M | |
| 2020 | 991,089 | $10.42M | |
| 2021 | 1,085,612 | $10.42M | |
| 2022 | 1,005,756 | $9.20M | |
| 2023 | 1,042,637 | $7.95M | |
| 2024incomplete | 786,252 | $5.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 13% | 125,848 | 107,900 | $7.87M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 6.1% | 190,425 | 158,628 | $3.77M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.9% | 191,009 | 159,136 | $3.65M |
| 80053 | Comprehensive metabolic panel | 3.5% | 531,474 | 467,525 | $2.18M |
| 80061 | Lipid panel | 3.5% | 424,276 | 366,101 | $2.16M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.2% | 126,086 | 108,193 | $1.95M |
| 84443 | Thyroid stimulating hormone (TSH) | 3.0% | 306,482 | 266,053 | $1.86M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.0% | 167,212 | 141,783 | $1.84M |
| 80050 | General health panel | 2.9% | 93,510 | 78,577 | $1.77M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.8% | 53,181 | 43,168 | $1.71M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.4% | 88,203 | 74,706 | $1.50M |
| 80081 | 2.3% | 25,070 | 21,565 | $1.44M |
417 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 449,260 | $1.41M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.0% | 49,906 | $1.24M |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.7% | 307,954 | $1.05M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.7% | 74,699 | $1.03M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.6% | 64,599 | $965K |
| 80074 | 1.1% | 39,618 | $700K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 1.1% | 20,438 | $689K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.1% | 98,837 | $667K |
| 86003 | 1.1% | 214,914 | $662K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.0% | 161,035 | $641K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 19,710 | $549K |
| 82607 | <1% | 85,215 | $505K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,065 | $475K |
| 87481 | <1% | 66,220 | $458K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 3,125 | $452K |
| 80055 | <1% | 14,727 | $442K | |
| 81514 | <1% | 4,123 | $437K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,324 | $405K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,475 | $374K |
| 86803 | <1% | 51,730 | $347K | |
| 81513 | <1% | 8,006 | $345K | |
| 84439 | <1% | 91,127 | $336K | |
| 87077 | <1% | 68,050 | $316K | |
| 82728 | <1% | 58,436 | $301K | |
| 87902 | <1% | 3,223 | $295K | |
| 84403 | <1% | 24,851 | $288K | |
| 88142 | <1% | 26,983 | $283K | |
| 81511 | <1% | 17,593 | $275K | |
| 82746 | <1% | 48,675 | $270K | |
| 86696 | <1% | 23,258 | $260K | |
| 84702 | <1% | 39,561 | $257K | |
| 87081 | <1% | 56,225 | $252K | |
| 87536 | <1% | 8,252 | $248K | |
| 87522 | Neg quan hep c or qual rna | <1% | 13,060 | $246K |
| 86592 | <1% | 98,793 | $245K | |
| 83970 | <1% | 22,224 | $244K | |
| 83655 | <1% | 31,333 | $221K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 70,851 | $220K |
| 83550 | <1% | 62,198 | $219K | |
| 83880 | <1% | 17,950 | $218K | |
| 86038 | <1% | 35,782 | $215K | |
| 85027 | <1% | 81,671 | $209K | |
| 84153 | <1% | 29,699 | $207K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,882 | $196K |
| 83540 | <1% | 74,004 | $192K | |
| 87186 | <1% | 48,052 | $189K | |
| 84481 | <1% | 23,901 | $184K | |
| 82670 | <1% | 12,756 | $181K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 332,717 | $179K |
| 87340 | <1% | 34,678 | $177K | |
| 82105 | <1% | 18,225 | $175K | |
| 87480 | <1% | 20,392 | $174K | |
| 88141 | <1% | 15,690 | $166K | |
| 86695 | <1% | 21,863 | $163K | |
| 86480 | <1% | 8,190 | $163K | |
| 83013 | <1% | 5,938 | $162K | |
| 86235 | <1% | 36,771 | $158K | |
| 83001 | <1% | 15,040 | $153K | |
| 82570 | <1% | 81,545 | $145K | |
| 83735 | <1% | 57,098 | $138K | |
| 87510 | <1% | 16,969 | $134K | |
| 84146 | <1% | 12,619 | $131K | |
| 86762 | <1% | 15,802 | $128K | |
| 83020 | <1% | 17,693 | $127K | |
| 84480 | <1% | 22,787 | $125K | |
| 87660 | <1% | 17,410 | $124K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 427 | $123K |
| 82785 | <1% | 13,978 | $118K | |
| 84270 | <1% | 10,735 | $118K | |
| 83002 | <1% | 11,348 | $114K | |
| 84144 | <1% | 10,190 | $113K | |
| 86665 | <1% | 8,980 | $113K | |
| 83525 | <1% | 16,552 | $110K | |
| 87070 | <1% | 23,688 | $109K | |
| 82043 | <1% | 55,765 | $106K | |
| 82677 | <1% | 6,195 | $104K | |
| 86703 | <1% | 10,827 | $101K | |
| 87799 | <1% | 18,574 | $99K | |
| 86769 | <1% | 4,735 | $95K | |
| 84436 | <1% | 36,087 | $90K | |
| 87511 | <1% | 7,900 | $88K | |
| 86376 | <1% | 11,767 | $87K | |
| 81001 | <1% | 66,457 | $86K | |
| 86140 | <1% | 38,278 | $83K | |
| 80164 | <1% | 14,243 | $81K | |
| 84550 | <1% | 39,426 | $81K | |
| 86850 | <1% | 16,711 | $80K | |
| 80076 | <1% | 24,647 | $76K | |
| 83516 | <1% | 23,069 | $71K | |
| 86431 | <1% | 26,248 | $71K | |
| 87507 | <1% | 344 | $69K | |
| 82950 | <1% | 22,251 | $69K | |
| 82248 | <1% | 30,153 | $69K | |
| 86336 | <1% | 6,211 | $67K | |
| 86787 | <1% | 8,429 | $67K | |
| 87631 | <1% | 799 | $65K | |
| 86360 | <1% | 4,681 | $64K | |
| 85652 | <1% | 47,900 | $60K | |
| 82784 | <1% | 22,033 | $59K | |
| 84681 | <1% | 7,171 | $58K | |
| 83690 | <1% | 16,363 | $56K | |
| 87653 | <1% | 2,607 | $56K | |
| 82627 | <1% | 4,300 | $55K | |
| 86359 | <1% | 4,691 | $54K | |
| 87512 | <1% | 3,717 | $53K | |
| 86800 | <1% | 6,876 | $53K | |
| 86706 | <1% | 11,091 | $50K | |
| 82652 | <1% | 3,452 | $49K | |
| 85660 | <1% | 11,200 | $48K | |
| 80177 | <1% | 7,632 | $46K | |
| 80349 | <1% | 5,279 | $46K | |
| 82150 | <1% | 13,709 | $45K | |
| 86225 | <1% | 9,685 | $45K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 4,873 | $45K |
| 87147 | <1% | 12,194 | $44K | |
| 86780 | <1% | 3,803 | $43K | |
| 87209 | <1% | 3,683 | $43K | |
| 86160 | <1% | 14,512 | $42K | |
| 84156 | <1% | 28,531 | $41K | |
| 80361 | <1% | 4,490 | $41K | |
| 84479 | <1% | 18,797 | $41K | |
| 86039 | <1% | 8,608 | $41K | |
| 82533 | <1% | 5,234 | $41K | |
| 82550 | <1% | 16,275 | $41K | |
| 84238 | <1% | 3,570 | $40K | |
| 83615 | <1% | 12,406 | $40K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 415 | $40K |
| 86200 | <1% | 7,308 | $38K | |
| 85610 | <1% | 26,109 | $38K | |
| 82947 | <1% | 16,735 | $38K | |
| 86664 | <1% | 3,286 | $37K | |
| 86704 | <1% | 7,855 | $37K | |
| 86677 | <1% | 4,541 | $37K | |
| 86147 | <1% | 4,665 | $36K | |
| 87205 | <1% | 14,717 | $36K | |
| 87255 | <1% | 1,841 | $35K | |
| 88342 | <1% | 1,417 | $34K | |
| 88112 | <1% | 1,964 | $34K | |
| 87451 | <1% | 15,815 | $34K | |
| 83021 | <1% | 3,450 | $33K | |
| 86901 | <1% | 15,241 | $33K | |
| 82951 | <1% | 4,836 | $32K | |
| 84165 | <1% | 11,294 | $31K | |
| 80069 | <1% | 13,651 | $31K | |
| 88307 | <1% | 610 | $31K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,766 | $31K |
| 86663 | <1% | 3,089 | $31K | |
| 87427 | <1% | 4,506 | $31K | |
| 82378 | <1% | 4,195 | $29K | |
| 87045 | <1% | 4,560 | $29K | |
| 86334 | <1% | 5,797 | $29K | |
| 82024 | <1% | 1,584 | $27K | |
| 80185 | <1% | 5,255 | $27K | |
| 86694 | <1% | 3,123 | $26K | |
| 83521 | <1% | 2,816 | $26K | |
| 86900 | <1% | 15,258 | $24K | |
| 84100 | <1% | 15,349 | $23K | |
| 86146 | <1% | 2,301 | $23K | |
| 85018 | <1% | 14,887 | $23K | |
| 87529 | <1% | 1,289 | $23K | |
| 82565 | <1% | 11,176 | $22K | |
| 81596 | <1% | 884 | $21K | |
| 87177 | <1% | 3,707 | $21K | |
| 86361 | <1% | 2,911 | $21K | |
| 83520 | <1% | 4,773 | $20K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 2,540 | $20K |
| 85014 | <1% | 12,898 | $20K | |
| 85045 | <1% | 10,709 | $20K | |
| 84703 | <1% | 4,786 | $20K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 11,264 | $20K |
| 80178 | <1% | 7,471 | $20K | |
| 84445 | <1% | 915 | $20K | |
| 87632 | <1% | 219 | $20K | |
| 86618 | <1% | 2,378 | $19K | |
| 80197 | <1% | 3,510 | $19K | |
| 85730 | <1% | 9,412 | $19K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 318 | $19K |
| 87276 | <1% | 2,036 | $18K | |
| 87046 | <1% | 4,573 | $18K | |
| 86757 | <1% | 2,152 | $18K | |
| 86258 | <1% | 1,848 | $17K | |
| 86705 | <1% | 2,772 | $17K | |
| 87493 | <1% | 548 | $17K | |
| 87275 | <1% | 2,037 | $16K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 563 | $16K |
| 83090 | <1% | 2,048 | $16K | |
| 82977 | <1% | 5,654 | $16K | |
| 86708 | <1% | 2,857 | $16K | |
| 86304 | <1% | 2,267 | $16K | |
| 86255 | <1% | 2,279 | $16K | |
| 84207 | <1% | 1,892 | $15K | |
| 84425 | <1% | 1,876 | $15K | |
| 84460 | <1% | 6,793 | $15K | |
| 85379 | <1% | 3,795 | $15K | |
| 82140 | <1% | 2,969 | $14K | |
| 84520 | <1% | 7,058 | $14K | |
| 86364 | <1% | 1,749 | $14K | |
| 84450 | <1% | 6,568 | $13K | |
| 83883 | <1% | 4,306 | $13K | |
| 86709 | <1% | 1,807 | $13K | |
| 82465 | <1% | 6,353 | $13K | |
| 80156 | <1% | 2,284 | $12K | |
| 87563 | <1% | 674 | $12K | |
| 82330 | <1% | 3,047 | $12K | |
| 81329 | <1% | 207 | $12K | |
| 87075 | <1% | 3,640 | $11K | |
| 87449 | <1% | 2,077 | $11K | |
| 86141 | <1% | 1,817 | $11K | |
| 80346 | <1% | 3,172 | $11K | |
| 88164 | <1% | 2,051 | $11K | |
| 80175 | <1% | 1,555 | $10K | |
| 82088 | <1% | 613 | $10K | |
| 87517 | <1% | 683 | $10K | |
| 88304 | <1% | 877 | $10K | |
| 87015 | <1% | 2,680 | $10K | |
| 84466 | <1% | 2,347 | $10K | |
| 85060 | <1% | 2,436 | $10K | |
| 87324 | <1% | 1,777 | $10K | |
| 82247 | <1% | 3,927 | $9K | |
| 86300 | <1% | 2,147 | $9K | |
| 83721 | <1% | 2,558 | $9K | |
| 87901 | <1% | 118 | $9K | |
| 81025 | <1% | 1,956 | $9K | |
| 84134 | <1% | 1,987 | $8K | |
| 86008 | <1% | 3,597 | $8K | |
| 86308 | <1% | 1,921 | $8K | |
| 80183 | <1% | 717 | $8K | |
| 84132 | <1% | 3,838 | $8K | |
| 83921 | <1% | 1,103 | $8K | |
| 82952 | <1% | 3,212 | $8K | |
| 80365 | <1% | 2,217 | $8K | |
| 83498 | <1% | 632 | $7K | |
| 82671 | <1% | 553 | $7K | |
| 86593 | <1% | 2,680 | $7K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 131 | $7K |
| 86231 | <1% | 844 | $7K | |
| 84155 | <1% | 7,927 | $7K | |
| 86812 | <1% | 656 | $7K | |
| 80324 | <1% | 1,333 | $7K | |
| 86036 | <1% | 896 | $6K | |
| 84484 | <1% | 1,482 | $6K | |
| 83010 | <1% | 1,578 | $6K | |
| 81003 | <1% | 7,919 | $6K | |
| 87102 | <1% | 1,541 | $6K | |
| 85007 | <1% | 4,146 | $6K | |
| 83695 | <1% | 1,072 | $6K | |
| 86015 | <1% | 575 | $6K | |
| 84432 | <1% | 838 | $5K | |
| 82668 | <1% | 1,037 | $5K | |
| 80364 | <1% | 872 | $5K | |
| 87206 | <1% | 2,441 | $5K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 107 | $5K |
| 82626 | <1% | 428 | $5K | |
| 82542 | <1% | 437 | $5K | |
| 83698 | <1% | 305 | $5K | |
| 83704 | <1% | 282 | $5K | |
| 80326 | <1% | 863 | $5K | |
| 86886 | <1% | 1,774 | $5K | |
| 80159 | <1% | 945 | $5K | |
| 80184 | <1% | 1,298 | $5K | |
| 87280 | <1% | 489 | $5K | |
| 80353 | <1% | 1,384 | $4K | |
| 80202 | <1% | 981 | $4K | |
| 82274 | <1% | 694 | $4K | |
| 87338 | <1% | 730 | $4K | |
| 84630 | <1% | 1,046 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 464 | $4K |
| 82397 | <1% | 753 | $4K | |
| 85240 | <1% | 490 | $4K | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 604 | $4K |
| 86381 | <1% | 439 | $4K | |
| P3001 | Screening papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician | <1% | 750 | $4K |
| 87273 | <1% | 845 | $4K | |
| 81015 | <1% | 4,117 | $4K | |
| 87088 | <1% | 781 | $3K | |
| 82040 | <1% | 1,749 | $3K | |
| 85613 | <1% | 1,162 | $3K | |
| 86341 | <1% | 402 | $3K | |
| 82232 | <1% | 1,039 | $3K | |
| 84075 | <1% | 1,813 | $3K | |
| P3000 | Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision | <1% | 471 | $3K |
| 84080 | <1% | 713 | $3K | |
| 80162 | <1% | 1,021 | $3K | |
| 82172 | <1% | 312 | $3K | |
| 84295 | <1% | 1,577 | $3K | |
| 80348 | <1% | 3,094 | $3K | |
| 86301 | <1% | 450 | $3K | |
| 86666 | <1% | 629 | $3K | |
| 84244 | <1% | 290 | $3K | |
| 80362 | <1% | 500 | $3K | |
| 86335 | <1% | 301 | $3K | |
| 80356 | <1% | 656 | $3K | |
| 84305 | <1% | 211 | $2K | |
| 82310 | <1% | 1,581 | $2K | |
| 80354 | <1% | 1,159 | $2K | |
| 82610 | <1% | 165 | $2K | |
| 87040 | <1% | 747 | $2K | |
| 87350 | <1% | 314 | $2K | |
| 82525 | <1% | 464 | $2K | |
| 84154 | <1% | 542 | $2K | |
| 87906 | <1% | 27 | $2K | |
| 87210 | <1% | 717 | $2K | |
| 86645 | <1% | 176 | $2K | |
| 82575 | <1% | 416 | $2K | |
| 87076 | <1% | 555 | $2K | |
| 85246 | <1% | 182 | $2K | |
| 84160 | <1% | 1,689 | $2K | |
| 80358 | <1% | 1,149 | $2K | |
| 85384 | <1% | 507 | $2K | |
| 84478 | <1% | 1,335 | $2K | |
| 86644 | <1% | 181 | $2K | |
| 82085 | <1% | 889 | $2K | |
| 86060 | <1% | 344 | $2K | |
| 89055 | <1% | 791 | $2K | |
| 83993 | <1% | 110 | $2K | |
| 87185 | <1% | 723 | $2K | |
| 82164 | <1% | 300 | $2K | |
| 85306 | <1% | 275 | $1K | |
| 86668 | <1% | 74 | $1K | |
| 84166 | <1% | 186 | $1K | |
| 87140 | <1% | 342 | $1K | |
| 82679 | <1% | 115 | $1K | |
| 80355 | <1% | 2,357 | $1K | |
| 80321 | <1% | 1,180 | $1K | |
| 85245 | <1% | 116 | $1K | |
| 84590 | <1% | 286 | $1K | |
| 85303 | <1% | 251 | $1K | |
| 85390 | <1% | 238 | $1K | |
| 86765 | <1% | 208 | $1K | |
| 86256 | <1% | 246 | $1K | |
| 82553 | <1% | 231 | $1K | |
| 85049 | <1% | 740 | $966.79 | |
| 86735 | <1% | 166 | $924.64 | |
| 82239 | <1% | 101 | $894.45 | |
| 86692 | <1% | 57 | $885.08 | |
| 81050 | <1% | 472 | $845.08 | |
| 80373 | <1% | 1,156 | $837.09 | |
| 82747 | <1% | 169 | $837.01 | |
| 80345 | <1% | 331 | $835.34 | |
| 83835 | <1% | 136 | $825.23 | |
| 86790 | <1% | 55 | $765.99 | |
| 86880 | <1% | 337 | $745.32 | |
| 82157 | <1% | 55 | $740.62 | |
| 88173 | <1% | 20 | $736.02 | |
| 85300 | <1% | 153 | $658.54 | |
| 81374 | <1% | 28 | $655.83 | |
| 82103 | <1% | 125 | $574.33 | |
| 86317 | <1% | 158 | $571.11 | |
| 80347 | <1% | 32 | $549.61 | |
| 84300 | <1% | 481 | $547.82 | |
| 83519 | <1% | 108 | $519.41 | |
| 84482 | <1% | 84 | $510.80 | |
| 86337 | <1% | 32 | $499.82 | |
| 86617 | <1% | 104 | $497.68 | |
| 80323 | <1% | 265 | $463.90 | |
| 80337 | <1% | 39 | $462.71 | |
| 86777 | <1% | 87 | $394.51 | |
| 87290 | <1% | 58 | $393.24 | |
| 80366 | <1% | 989 | $390.28 | |
| 82270 | <1% | 247 | $379.04 | |
| 83789 | <1% | 65 | $369.04 | |
| 80299 | <1% | 13 | $343.59 | |
| 82390 | <1% | 80 | $318.37 | |
| 88302 | <1% | 14 | $314.64 | |
| 86702 | <1% | 145 | $310.82 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 158 | $241.50 |
| 80360 | <1% | 253 | $232.56 | |
| 80051 | <1% | 61 | $232.50 | |
| 85307 | <1% | 67 | $231.48 | |
| 88155 | <1% | 65 | $229.71 | |
| 84255 | <1% | 15 | $228.44 | |
| 86162 | <1% | 31 | $226.65 | |
| 80235 | <1% | 12 | $222.99 | |
| 86870 | <1% | 37 | $218.88 | |
| 86316 | <1% | 27 | $211.51 | |
| 87252 | <1% | 22 | $209.70 | |
| 86701 | <1% | 145 | $204.04 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 323 | $203.59 |
| 87116 | <1% | 70 | $202.32 | |
| 86753 | <1% | 30 | $197.96 | |
| 82166 | <1% | 14 | $193.50 | |
| 80201 | <1% | 66 | $184.48 | |
| 89060 | <1% | 29 | $178.61 | |
| 83935 | <1% | 77 | $171.90 | |
| 84260 | <1% | 15 | $169.42 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 21 | $150.00 |
| 85576 | <1% | 17 | $147.18 | |
| 82435 | <1% | 101 | $143.07 | |
| 83992 | <1% | 233 | $139.69 | |
| 88313 | <1% | 30 | $139.57 | |
| 82180 | <1% | 44 | $138.53 | |
| 87269 | <1% | 12 | $131.57 | |
| 82787 | <1% | 156 | $126.38 | |
| 87425 | <1% | 16 | $115.44 | |
| 83930 | <1% | 53 | $108.34 | |
| 84446 | <1% | 13 | $107.50 | |
| 85048 | <1% | 56 | $104.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 20 | $103.56 |
| 86707 | <1% | 27 | $102.86 | |
| 80371 | <1% | 211 | $91.84 | |
| 85230 | <1% | 16 | $77.25 | |
| 82374 | <1% | 55 | $64.13 | |
| 80173 | <1% | 20 | $62.37 | |
| 83014 | <1% | 16 | $51.01 | |
| 82540 | <1% | 36 | $49.45 | |
| 87497 | <1% | 13 | $42.25 | |
| 87385 | <1% | 15 | $26.54 | |
| 82340 | <1% | 12 | $26.47 | |
| 82955 | <1% | 12 | $19.37 | |
| 84145 | <1% | 18 | $13.61 | |
| 36416 | <1% | 119 | $0.09 | |
| 80369 | 0% | 200 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 26 | $0.00 |
| 99000 | 0% | 3,513 | $0.00 | |
| 80368 | 0% | 205 | $0.00 | |
| 87483 | 0% | 48 | $0.00 | |
| 80188 | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVALLADARES, DINA (SENIOR DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Propath Services, LLC | Dallas, TX | $16.79M |
| Seacoast Pathology INC | Exeter, NH | $995K |
| Pinkus Dermatopathology Laboratory, PC | Monroe, MI | $816K |
| Bernhardt Laboratories INC | Jacksonville, FL | $620K |
| Cleveland Skin Pathology Laboratory, INC | Beachwood, OH | $609K |
| Carla B. Macleod M.D. & Associates LLC | Gaithersburg, MD | $292K |
| Biopsy Diagnostics, LLC | Ridgeland, SC | $255K |
| Pinkus Dermatopathology Laboratory, PC | Monroe, MI | $93K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.